Speaker Profile

MBA, CEO, KIT Bio, Inc.
Biography

Ted Snelgrove is an industry veteran with over 30 years of leadership experience in marketing and corporate development, primarily driving early commercialization for innovative products that bring disruptive technology to medicine. He has built high-performing teams in both the therapeutics and molecular diagnostics fields. Ted was the first commercial hire for Genomic Health in 2001 where he influenced product design, built the first commercial team and established the initial pricing model for Oncotype Dx. This created an “umbrella pricing” effect that supported the proliferation of new companies in the molecular diagnostic space. He was the second employee and Chief Commercial Officer at Crescendo Bioscience, now part of Myriad, introducing the first quantitative tracking system for patients being treated for rheumatoid arthritis. He later was CEO at CellScape, and Chief Business Officer for Counsyl, both in the field of reproductive medicine.

Clinical Dx Showcase: KIT Bio, Inc.
KIT Bio is developing medical devices for broad deployment to support personalized kidney disease management with quantitative diagnostic systems.

Kidney Disease Management: A Novel System For Quantitative Assessment
In the Kidney Disease field, weak biomarkers that limit personalization and complicate drug development have slowed medical innovation. At KIT Bio, we are developing a simple, accurate and affordable system to support serial tracking of patients with impaired renal function to address this problem.

Speaker Profile

MBA, CEO, KIT Bio, Inc.
Biography

Ted Snelgrove is an industry veteran with over 30 years of leadership experience in marketing and corporate development, primarily driving early commercialization for innovative products that bring disruptive technology to medicine. He has built high-performing teams in both the therapeutics and molecular diagnostics fields. Ted was the first commercial hire for Genomic Health in 2001 where he influenced product design, built the first commercial team and established the initial pricing model for Oncotype Dx. This created an “umbrella pricing” effect that supported the proliferation of new companies in the molecular diagnostic space. He was the second employee and Chief Commercial Officer at Crescendo Bioscience, now part of Myriad, introducing the first quantitative tracking system for patients being treated for rheumatoid arthritis. He later was CEO at CellScape, and Chief Business Officer for Counsyl, both in the field of reproductive medicine.

Clinical Dx Showcase: KIT Bio, Inc.
KIT Bio is developing medical devices for broad deployment to support personalized kidney disease management with quantitative diagnostic systems.

Kidney Disease Management: A Novel System For Quantitative Assessment
In the Kidney Disease field, weak biomarkers that limit personalization and complicate drug development have slowed medical innovation. At KIT Bio, we are developing a simple, accurate and affordable system to support serial tracking of patients with impaired renal function to address this problem.

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To receive the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!